D.A. Davidson Reaffirms Their Buy Rating on Akamai (AKAM)
D.A. Davidson analyst Rudy Kessinger maintained a Buy rating on Akamai (AKAM – Research Report) yesterday and set a price target of $120.00.
"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...